LIANA VALENTE LAGE
Índice h a partir de 2011
2
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Radiologia, Hospital das Clínicas, Faculdade de Medicina
6 resultados
Resultados de Busca
Agora exibindo 1 - 6 de 6
conferenceObject Safety and efficacy of adjuvant modified FLOX for patients (pts) with stage III colorectal cancer (CRC) treated in the community.(2015) PROTASIO, Bruno Mendonca; MATUTINO, Adriana Reis Brandao; LAGE, Liana Valente; SANTANA, Iuri Amorim De; RAMOS, Ricardo Emanuel De Oliveira; CAIRES-LIMA, Rafael; CAIRES, Inacelli Queiroz De Souza; RIECHELMANN, Rachel Pimenta; SARAGIOTTO, Daniel Fernandes; SABBAGA, Jorge; HOFF, Paulo MarceloconferenceObject Efficacy and tolerability of Docetaxel in patients with metastatic castrate-resistant prostate cancer older than 70 years compared with younger patients(2015) MAIA, M. C. Dias Ferreira; FRAILE, N. Moreno Perez; LAGE, L. Valente; SOUZA, R. Barosso; DZIK, C.; BASTOS, D. Assed; VAISBERG, V. Van- The role of platinum rechallenge as second line chemotherapy for metastatic endometrial carcinoma.(2016) SOUZA, Ronaldo Pereira; SOARES, Gregorio Pinheiro; LAGE, Liana Valente; FANELLI, Marcello Ferretti; SANCHES, Solange Moraes; GUIMARAES, Andrea Paiva G.; RIBEIRO, Adriana Regina G.; SAITO, Augusto; COSTA, Alexandre Andre Balieiro Anastacio da; ESTEVEZ-DIZ, Maria Del Pilar
- Efficacy and Safety of Docetaxel in Elderly Patients With Metastatic Castration-Resistant Prostate Cancer(2017) MAIA, Manuel Caitano; PEREIRA, Allan A. Lima; LAGE, Liana Valente; FRAILE, Natalia Moreno; VAISBERG, Victor Van; KUDO, Guilherme; BARROSO-SOUSA, Romualdo; BASTOS, Diogo Assed; DZIK, CarlosPurpose Limited data are available about the tolerability and clinical outcomes of elderly patients with metastatic castration-resistant prostate cancer (mCRPC) who are treated with docetaxel. We evaluated the efficacy and safety of docetaxel as first-line chemotherapy for patients with mCRPC who were treated in our institution. Materials and Methods We retrospectively identified patients with mCRPC and a Karnosfky performance status of 60% or greater treated with docetaxel on any schedule as first-line chemotherapy between 2008 and 2013. The primary end point was a comparison of median overall survival (OS) according to age in this population. Secondary end points were comparisons of the rates of severe toxicities, prostate-specific antigen (PSA) decline of 50% or greater, and time to progression (TTP). Results were stratified by three age groups: younger than 65 years, 65 to 74 years, and 75 years or older. Results Among the 197 patients included, 68 (34%) were younger than 65 years, 85 (43%) were 65 to 74 years, and 44 (22%) were 75 years or older. The mean number of comorbidities was not different among groups (1.19 v 1.32 v 1.43; P = .54). Patients younger than 65 years received a higher cumulative dose of docetaxel (450 mg/m(2)v 382 mg/m(2)v 300 mg/m(2); P = .004). The rates of PSA decline of 50% or greater (41% v 47% v 36.4%; P = .51) and the median TTP (5.13 v 5.13 v 4.7 months; P = .15) were comparable among all groups. The median OS was longer in the group of patients younger than age 65 years (19.6 v 12.4 v 12.3 months; P = .012). Rates of any grade 3 or higher adverse event were not different among groups (63.2% v 71.8% v 54.5%; P = .14). Conclusion Administration of docetaxel in elderly patients who had good performance status was well tolerated. Rates of PSA decline and TTP were similar to those of younger patients, but median survival was lower. (C) 2017 by American Society of Clinical Oncology
conferenceObject Retrospective analysis of prognostic factors in patients undergoing surgical resection for multiple brain metastases(2014) PETITTO, Carlos; LAGE, Liana Valente; CAIRES, Inacelli Queiroz De Souza; SOUZA, Karla T.; FEDE, Angelo Bezerra de Souza; FEHER, Olavo; HOFF, Paulo M.; CAMARGO, Verldlana; MENCARINI, Ana; MUNHOZ, Rodrigo Ramella; TEIXEIRA, Manoel Jacobsen; LEPSKI, Guilherme- Safety and Efficacy of a Modified FLOX Adjuvant Regimen for Patients With Stage III Colorectal Cancer Treated in the Community(2017) PROTASIO, Bruno Mendonca; MATUTINO, Adriana; LAGE, Liana Valente; SANTANA, Iuri; RAMOS, Ricardo; SABBAGA, Jorge; CAPARELI, Fernanda; SARAGIOTTO, Daniel; RIECHELMANN, Rachel; HOFF, Paulo M.The efficacy and safety of adjuvant modified FLOX (combination of oxaliplatin with a bolus regimen of fluorouracil) for patients with stage III colorectal cancer were analyzed retrospectively. A total of 267 patients were included, with a 74.9% rate of a 2-year disease-free survival and a Grade >= 3 toxicity rate of 36.7%. Age 70 years or older was associated with a higher risk of Grade >= 3 adverse events, suggesting that adjuvant oxaliplatin should be restricted to patients younger than 70 years. Background: The efficacy and safety of the combination of a fluoropyrimidine with oxaliplatin for patients with stage III colorectal cancer (CRC) have been evaluated in selected patients who took part in clinical trials. We evaluated the outcomes of FLOX (bolus fluorouracil [5-FU] combined with oxaliplatin) in patients with resected stage III CRC treated in the community in a large cancer center. Patients and Methods: We performed a retrospective unicenter cohort study of all consecutive stage III CRC patients who received adjuvant chemotherapy with an mFLOX (modified FLOX) regimen. The schedule consisted of 5-FU bolus 500 mg/m(2) and bolus of leucovorin 20 mg/m(2) per week for 6 consecutive weeks and oxaliplatin 85 mg/m(2) in a 2-hour infusion at weeks 1, 3, and 5, every 8 weeks. Logistic regression multivariate analyses were used to evaluate prognostic factors for relapse at 2 years, and to investigate potential predictors of Grade >= 3 toxicity. Results: A total of 267 consecutive patients were eligible and included. The median age was 59 years and pathological stage was mostly IIIB (68.2%). With a median follow-up of 24 months, n = 67 patients (25.1%) relapsed, representing a 74.9% rate of disease-free survival at 2 years. In multivariable analyses, urgent surgery (odds ratio [OR], 1.89; 95% confidence interval [CI], 1.02-3.48; P =.042), angiolymphatic invasion (OR, 1.92; 95% CI, 1.05-3.52; P =.034), and any interruption or dose reduction of chemotherapy (OR, 2.37; 95% CI, 1.31-4.27; P =.004) were predictors of recurrence or death at 2 years. Nine patients (3.4%) died from any cause within 60 days of starting mFLOX. Grade >= 3 toxicity occurred in 98 (36.7%) patients, with diarrhea (n = 43; 16.1%) and neutropenia (n = 38; 15.3%) being the most frequent ones. Peripheral neurotoxicity Grade >= 3 occurred in 5 patients (1.8%). Age 70 years or older (OR, 5.85; 95% CI, 2.5-13.66; P <=.001) was independently associated with a higher risk of a Grade >= 3 adverse events. Conclusion: Results suggest that the effectiveness of combining oxaliplatin with bolus 5-FU in patients in the community is reasonably similar to that obtained in clinical trials. However, community patients presented a higher risk of death, especially for those who were older than 70 years. Adjuvant oxaliplatin should be used carefully and probably restricted to fit patients younger than 70 years in this setting.